参麦注射液联合美托洛尔治疗心力衰竭临床研究  

Clinical Study on Shenmai Injection Combined with Metoprolol for Heart Failure

作　　者：宋爽[1] 王磊[2] 董加建 SONG Shuang;WANG Lei;DONGJiajian(Department of Cardiology,The 7th People's Hospital of Zhengzhou,Zhengzhou Henan 450000,China;Department of Cardiology,The First Affiliated Hospital of Henan University of Chinese Medicine,Zhengzhou Henan 450000,China)

机构地区：[1]郑州市第七人民医院心内科,河南郑州450000 [2]河南中医药大学第一附属医院心内科,河南郑州450000

出　　处：《新中医》2023年第17期72-76,共5页New Chinese Medicine

摘　　要：目的:观察参麦注射液联合美托洛尔治疗心力衰竭的临床疗效。方法:选择80例心力衰竭患者为研究对象,按随机数字表法分为2组各40例。研究组采用参麦注射液联合美托洛尔治疗,对照组仅使用美托洛尔治疗,连续治疗14 d。治疗后比较2组临床疗效,并比较2组治疗前后心功能指标及血清高迁移率族蛋白B1(HMGB1)、晚期糖基化终产物受体(RAGE)、N端脑钠肽前体(NT-proBNP)表达水平。门诊及电话随访12个月,比较2组心血管事件发生情况。结果:研究组治疗总有效率95.00%,高于对照组72.50%(P<0.05)。治疗前,2组左心室舒张末期内径(LVEDD)、左心室收缩期末期内径(LVESD)、左心室射血分数(LVEF)比较,差异无统计学意义(P>0.05);治疗后,2组LVEDD、LVESD降低(P<0.05),LVEF升高(P<0.05),且研究组LVEDD、LVESD低于对照组(P<0.05),LVEF高于对照组(P<0.05)。治疗前,2组血清HMGB1、RAGE、NT-proBNP水平比较,差异无统计学意义(P>0.05);治疗后,2组血清HMGB1、RAGE、NT-proBNP水平均降低(P<0.05),且研究组低于对照组(P<0.05)。研究组心血管事件总发生率为7.50%,低于对照组25.00%(P<0.05)。结论:参麦注射液联合美托洛尔治疗心力衰竭患者,可提高临床疗效,改善心功能指标,降低心血管事件发生率。Objective:To observe the clinical effect of Shenmai Injection combined with Metoprolol for heart failure.Methods:A total of 80 cases of patients with heart failure were selected as the study objects and divided into two groups according to the random number table method,with 40 cases in each group.The study group was treated with Shenmai Injection combined with Metoprolol,and the control group was simply treated with Metoprolol.Both groups were treated for 14 days.After treatment,the clinical effects were compared between the two groups.Before and after treatment,and the heart function indexes and the expression levels of high mobility group protein B1(HMGB1),receptor for advanced glycation end products(RAGE)and N-terminal pro-brain natriuretic peptide(NT-proBNP)in serum were compared between the two groups.After 12-month outpatient and telephone follow-up,the incidence of cardiovascular events was compared between the two groups.Results:The total effective rate was 95.00%in the study group,higher than that of 72.50%in the control group(P<0.05).Before treatment,there was no significant difference being found in the comparison of left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVESD),and left ventricular ejection fraction(LVEF)between the two groups(P>0.05).After treatment,LVEDD and LVESD in the two groups were decreased(P<0.05),and LVEF was increased(P<0.05);LVEDD and LVESD in the study group were lower than those in the control group(P<0.05),and LVEF was higher than that in the control group(P<0.05).Before treatment,there was no significant difference being found in the comparison of the levels of HMGB1,RAGE,and NT-proBNP in serum between the two groups(P>0.05).After treatment,the levels of HMGB1,RAGE,and NT-proBNP in serum in the two groups were decreased(P<0.05),and the above levels in the study group were lower than those in the control group(P<0.05).The total incidence of cardiovascular events was 7.50%in the study group,lower than that of 25.00%in the control group(P<0.

关 键 词：心力衰竭 参麦注射液 美托洛尔 心血管事件 心功能 

分 类 号：R541.6[医药卫生—心血管疾病]